Melt Pharmaceuticals has entered into an exclusive development and license agreement with Catalent for its Zydis fast-dissolve technology. The technology will be used in MELT-300, a needle- and opioid-free formulation for procedural sedation during cataract surgery. MELT-300, which combines fixed doses of midazolam and ketamine, is administered sublingually and uses Zydis ODT technology to rapidly dissolve the tablet for absorption. Melt Pharmaceuticals is currently in discussions with the FDA on the Phase 3 program, which is expected to begin in early 2024.